24 June 2026
Latham & Watkins Advises on Adaptive Biotechnologies’ Upsized US$300 Million Convertible Senior Notes Offering
Advising firms
Deal team
14 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Michael Benjamin Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Greg Rodgers Lead | Latham & Watkins LLP | Partner | corporate | New York/Los Angeles |
| Scott Westhoff Lead | Latham & Watkins LLP | Partner | corporate | Chicago |
| Andrew Blumenthal Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Andrew Rutsky | Latham & Watkins LLP | Associate | corporate | Not stated |
| Andrew Bentz | Latham & Watkins LLP | Associate | corporate | Not stated |
| Tony Noh | Latham & Watkins LLP | Associate | corporate | Not stated |
| Helen Zhang | Latham & Watkins LLP | Associate | corporate | Not stated |
| Lydia Kim | Latham & Watkins LLP | Associate | corporate | Not stated |
| Rene de Vera | Latham & Watkins LLP | Partner | tax | Chicago |
| Jack Santoro | Latham & Watkins LLP | Associate | tax | Not stated |
| Eric Rice | Latham & Watkins LLP | Partner | derivatives | New York |
| Sloan Ungerman | Latham & Watkins LLP | Associate | derivatives | Not stated |
| Daniel Weiss | Latham & Watkins LLP | Associate | derivatives | Not stated |
11 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 300m (US$300 million)
- What the figure measures
- Issue size
- Client
- Latham & Watkins LLPUnderwriters
- Counterparties
- Adaptive Biotechnologies Corporation (Issuer)